Log in

Relevant bibliographies by topics / SNP309 / Journal articles

To see the other types of publications on this topic, follow the link: SNP309.

Journal articles on the topic 'SNP309'

Author: Grafiati

Published: 4 June 2021

Last updated: 10 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'SNP309.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Miedl, Heidi, Jürgen Lebhard, Lisa Ehart, and Martin Schreiber. "Association of the MDM2 SNP285 and SNP309 Genetic Variants with the Risk, Age at Onset and Prognosis of Breast Cancer in Central European Women: A Hospital-Based Case-Control Study." International Journal of Molecular Sciences 20, no. 3 (2019): 509. http://dx.doi.org/10.3390/ijms20030509.

Full text

Abstract:

SNP309T>G (rs2279744) and SNP285G>C (rs117039649) in the MDM2 promoter are thought to have opposite effects on the binding of transcription factor SP1 (specificity protein 1), and consequently on MDM2 expression, p53 levels, cancer risk, age at onset, and prognosis. Here, we genotyped SNP309 and SNP285 in 406 Austrian breast cancer patients and 254 female controls. The SNP309GG genotype was associated with an increased breast cancer risk in p53 negative (OR, 1.82; 95% CI, 1.09–3.03; p = 0.02), but not p53 positive or unselected patients. In contrast, the SNP309TT genotype was associated

APA, Harvard, Vancouver, ISO, and other styles

2

Mackay, H. J., P. Bradbury, K. Asomaning, et al. "Stage and histology influence the relationship between MDM2 promoter polymorphism and esophageal cancer and overall survival (OS)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 21047. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.21047.

Full text

Abstract:

21047 Background: A single nucleotide polymorphism in the MDM2 promoter (SNP309) has been found to affect OS of advanced stage gastric adenocarcinoma (AD) and early stage squamous (SQ) cell carcinoma of the lung. The aim of this study was to evaluate the role of this polymorphism in the prognosis of esophageal cancer, another aerodigestive cancer. Methods: 150 early stage (E) and 118 locally advanced stage (LA) esophageal cancers were genotyped for MDM2 SNP309 using Taqman. The primary endpoint was overall survival (OS). Results: E disease: n=23 stage I; n=127 stage II. LA disease: n=93, Stage

APA, Harvard, Vancouver, ISO, and other styles

3

Gryshchenko, Irina, Sebastian Hofbauer, Markus Stoecher, et al. "MDM2 SNP309 Is Associated With Poor Outcome in B-Cell Chronic Lymphocytic Leukemia." Journal of Clinical Oncology 26, no. 14 (2008): 2252–57. http://dx.doi.org/10.1200/jco.2007.11.5212.

Full text

Abstract:

Purpose A single nucleotide polymorphism (SNP) at position 309 in the promoter region of MDM2 leading to increased expression of MDM2 and attenuated function of p53 has been negatively associated with onset and outcome of disease in solid tumors. Because inactivation of p53 by deletion and/or mutations also impacts on the clinical course of B-cell chronic lymphocytic leukemia (B-CLL), we assessed the role of the SNP309 genotype in B-CLL. Patients and Methods The frequency of SNP309 T/T, T/G, or G/G genotypes and the p53 status (wild type, mutated, or deleted) were assessed and correlated with

APA, Harvard, Vancouver, ISO, and other styles

4

Ohmiya, Naoki, Ayumu Taguchi, Nobuyuki Mabuchi, et al. "MDM2Promoter Polymorphism Is Associated With Both an Increased Susceptibility to Gastric Carcinoma and Poor Prognosis." Journal of Clinical Oncology 24, no. 27 (2006): 4434–40. http://dx.doi.org/10.1200/jco.2005.04.1459.

Full text

Abstract:

PurposeRecently, a single-nucleotide polymorphism in the MDM2 promoter (SNP309) has been found to lower the age of onset of tumors and increase the occurrence of multiple primary tumors in Li-Fraumeni syndrome, and accelerate the development of sporadic adult soft tissue sarcoma. The aim of this study was to determine whether SNP309 is associated with susceptibility to gastric carcinoma and its prognosis.Patients and MethodsIn a case-control study including 438 controls and 410 patients with sporadic gastric carcinoma, MDM2 SNP309 was genotyped. Serum pepsinogens (PGs) I and II were measured i

APA, Harvard, Vancouver, ISO, and other styles

5

Dong, Hua-Jie, Cheng Fang, Lei Fan, et al. "MDM2 Promoter SNP309 Is Associated with An Increased Susceptibility to Chronic Lymphocytic Leukemia and Correlates with MDM2 mRNA Expression In Chinese Population." Blood 116, no. 21 (2010): 2424. http://dx.doi.org/10.1182/blood.v116.21.2424.2424.

Full text

Abstract:

Abstract Abstract 2424 Objective: A single nucleotide polymorphism (SNP) at position 309 in the promoter region of MDM2 leading to increased expression of MDM2 and attenuated function of p53 has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. Because inactivation of p53 by deletion and/or mutations also impacts on the clinical course of CLL, we assessed the role of the SNP309 genotype in CLL among Chinese populations. Methods: The MDM2 SNP309 genotypes in 166 CLL patients and 260 healthy controls were detected

APA, Harvard, Vancouver, ISO, and other styles

6

Pine, S. R. "MDM2 SNP309 and SNP354 Are Not Associated with Lung Cancer Risk." Cancer Epidemiology Biomarkers & Prevention 15, no. 8 (2006): 1559–61. http://dx.doi.org/10.1158/1055-9965.epi-06-0217.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Nechushtan, H., T. Hamburger, S. Mendelson, et al. "Superior survival of breast cancer BRCA1 /2 mutation carriers harboringG/G at the -309 position at the MDM2 promoter compared to those harboring T/T or G/T at this SNP." Journal of Clinical Oncology 25, no. 18_suppl (2007): 10600. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.10600.

Full text

Abstract:

10600 Background: A germ line single polymorphism in the promoter of the gene encoding the important modulator of P53, MDM2 has been described. The findings of G/G nucleotides at this position in contrast to G/Tor T/T were demonstrated to increase MDM2 transcriptional levels and were correlated with younger onset of cancers in patients with the Li-Fraumeni syndrome. Furhtermore gastric cancer patients harboring T/T at this position and treated with chemotherapy were found to have decresed survival compared to the other SNP carriers. P53 mutations appear in high frequency in tumors associated w

APA, Harvard, Vancouver, ISO, and other styles

8

Lee, Hyunjoo, Anthony Liew, Annette Lee, et al. "Effect of Polymorphisms in p53 Pathway Proteins and B-Chronic Lymphocytic Leukemia Disease Progression,." Blood 118, no. 21 (2011): 3888. http://dx.doi.org/10.1182/blood.v118.21.3888.3888.

Full text

Abstract:

Abstract Abstract 3888 In B-CLL, mutations in the IGHV genes encoding the BCR are correlated with disease aggressiveness: patients with unmutated BCR (U-CLL) typically have a worse prognosis than those with mutated BCR (M-CLL). Evidence that many U-CLL express BCR with specificity toward apoptotic cell antigens suggests that dying cells provide pro-survival signals for U-CLL clones. Thus progression of U-CLL may depend both on mechanisms that ensure the clone's survival and those that promote cell death. A single nucleotide polymorphism (SNP) within the p53 gene at codon 72 significantly affec

APA, Harvard, Vancouver, ISO, and other styles

9

Vivenza, Daniela, Martino Monteverde, Laura Lattanzio, et al. "Correlation of TP53 and MDM2 Genotypes and Clinical Outcome in Platinum-Treated Head and Neck Cancer Patients with More than 10 Years’ Follow-Up." International Journal of Biological Markers 31, no. 2 (2016): 183–92. http://dx.doi.org/10.5301/jbm.5000192.

Full text

Abstract:

Purpose Adequate biomarkers are still required to optimize therapy in patients with locally advanced head and neck squamous carcinomas (HNSCC) treated with chemoradiotherapy (CRT). Methods We updated the follow-up of 66 HNSCC patients treated with CRT we described more than 10 years ago, focusing on SNP Arg/Pro (R/P) at codon 72 and somatic mutations in TP53 and on SNP309 in the MDM2 gene. Results In wild-type TP53 cases, overall survival (OS) was longer in 72RR and less favorable in 72PP (p = 0.005); when TP53 was mutated, OS was longest in 72PP and less favorable in 72RR and 72RP (p = 0.058)

APA, Harvard, Vancouver, ISO, and other styles

10

Sun, S., X. Xie, J. H. Schiller, J. D. Minna, and G. Tomlinson. "The functional MDM2 SNP309 polymorphism is associated with an earlier age of diagnosis in women with lung cancer." Journal of Clinical Oncology 25, no. 18_suppl (2007): 10550. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.10550.

Full text

Abstract:

10550 Background: MDM2 protein is a key negative regulator of p53 protein by targeting its destruction through the ubiquitin pathway. A single nucleotide polymorphism (SNP309 T→G) has been identified in the promoter of the MDM2 gene which results in higher levels of MDM2 protein, attenuation of the p53 pathway, and enhanced tumorigenesis. Estrogen signaling has also been shown to upregulate MDM2 expression. Recent studies have suggested that the MDM2 SNP309 polymorphism is associated with earlier age of onset of certain cancers, particularly in women. The purpose of this study was to determine

APA, Harvard, Vancouver, ISO, and other styles

11

Hevroni, Avigdor, Svetlana Krichevsky, Susana Mustafa, Nadir Arber, and Dina Ben-Yehuda. "Mdm2 SNP309 Different Genotypes Distribution in Israeli Population and in Patients with Hematological Malignancies." Blood 106, no. 11 (2005): 4395. http://dx.doi.org/10.1182/blood.v106.11.4395.4395.

Full text

Abstract:

Abstract P53 is a pivotal tumor suppressor gene that is mutated in half of all human cancers. The Mdm2 protein is a major negative regulator of p53. At residue 309 of the Mdm2 gene, there is a single nucleotide polymorphism (SNP) with a T-to-G substitution. Residue 309 is located in the first intron which is the locus of a P53-responsive promoter. The frequencies of the Mdm2 SNP309 variant genotypes have been reported to be 12% G/G, 40% G/T and 48% to T/T (Bond et.al. Cell 2004, Cancer Research 2005). Recent studies in cell lines (Ibid) showed that the G/G genotype confers an increased affinit

APA, Harvard, Vancouver, ISO, and other styles

12

He, Xuepeng, Peng Chen, Kai Yang, et al. "Association of MDM2 Polymorphism with Risk and Prognosis of Leukemia: A Meta-Analysis." Acta Haematologica 133, no. 4 (2015): 365–71. http://dx.doi.org/10.1159/000369522.

Full text

Abstract:

Objective: In this study, we performed an updated meta-analysis by summarizing all available relevant association studies to evaluate whether the murine double minute-2 (MDM2) T309G polymorphism is associated with risk of leukemia and to determine its prognostic effect. Material and Methods: Studies published in PubMed, Embase and the Cochrane Controlled Trial Register were searched till June 2014 using the search terms ‘MDM2', ‘polymorphism' and ‘leukemia'. Results: Eleven studies were included in this meta-analysis, with a total of 2,478 patients accrued. There were 8 studies providing data

APA, Harvard, Vancouver, ISO, and other styles

13

Taş, Ayca, İsmail Sari, Tuğba Ağbektaş, and Yavuz Siliğ. "MDM2 SNP309 polymorphism in Turkish population." Cumhuriyet Medical Journal 39, no. 4 (2017): 644–51. http://dx.doi.org/10.7197/223.v39i32356.369012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

McGraw, Kathy L., Lan Min Zhang, William Fulp, et al. "Association of MDM2 Gene Polymorphisms SNP285 and 309 with Myelodysplastic Syndromes (MDS) Susceptibility and Outcome." Blood 120, no. 21 (2012): 2823. http://dx.doi.org/10.1182/blood.v120.21.2823.2823.

Full text

Abstract:

Abstract Abstract 2823 Background: Mutations in TP53, or less often its regulators, increases risk for malignant transformation. Murine double minute protein 2 (MDM2), an E3 ubiquitin ligase, targets p53 for proteasomal degradation and is the most well studied negative regulator of p53. Recent investigations have highlighted the emerging importance of p53 in MDS. Haploinsufficiency for ribosomal protein S14 in deletion 5q MDS liberates free ribosomal proteins that bind to and promote degradation of MDM2, thereby activating p53 in erythroid precursors. A single nucleotide polymorphism (SNP) in

APA, Harvard, Vancouver, ISO, and other styles

15

Capasso, Mario, Fabrizio Ayala, Rosa Anna Avvisati, et al. "MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness." Journal of Human Genetics 55, no. 8 (2010): 518–24. http://dx.doi.org/10.1038/jhg.2010.62.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Dufour, Annika, Stefan K. Bohlander, Evelyn Zellmeier, et al. "Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,." Blood 118, no. 21 (2011): 3521. http://dx.doi.org/10.1182/blood.v118.21.3521.3521.

Full text

Abstract:

Abstract Abstract 3521 MicroRNA-34a (miR-34a), a direct downstream target of the tumor suppressor TP53 is upregulated in chronic lymphocytic leukemia (CLL) cells and leads to apoptosis and cell cycle arrest. Previous studies found low miR-34a expression levels in CLL patients with TP53 gene disruptions by either 17p13 deletions or TP53 mutations and this has been linked to chemotherapy resistance and poor prognosis. Alternatively, miR-34a expression levels might be influenced by a single nucleotide polymorphism 309 (SNP 309) in the intronic MDM2 promoter. In this work we retrospectively determ

APA, Harvard, Vancouver, ISO, and other styles

17

Toyama, T., Z. Zhang, M. Hamguchi, et al. "Association of p53 codon 72 polymorphism with resistance to adjuvant therapy in primary breast cancer." Journal of Clinical Oncology 25, no. 18_suppl (2007): 10520. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.10520.

Full text

Abstract:

10520 Background: Single-nucleotide polymorphisms (SNPs) in codon 72 of the p53 gene and in the promoter region of the MDM2 gene (SNP309) have been suggested to play a role in many cancers. We investigated whether these SNPs were associated with patient outcome and influence of adjuvant systemic therapy. Method: The genotypes of p53 codon 72 and MDM2 SNP309 were defined among 557 primary Japanese breast cancer patients (median follow-up, 61.7 months). The effects of several variables on survival were tested by Cox's proportional hazards regression analysis. Results: We showed that the Pro/Pro

APA, Harvard, Vancouver, ISO, and other styles

18

Firoz, E., M. A. Warycha, R. L. Shapiro, et al. "MDM2 SNP309 and melanoma risk among women." Journal of Clinical Oncology 26, no. 15_suppl (2008): 11099. http://dx.doi.org/10.1200/jco.2008.26.15_suppl.11099.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Knappskog, Stian, and Per Eystein Lønning. "MDM2 SNP309 and risk of cervical cancer." Tumor Biology 35, no. 7 (2014): 6185–86. http://dx.doi.org/10.1007/s13277-014-1910-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Knappskog, Stian, and Per Eystein Lønning. "MDM2 SNP309 and risk of endometrial cancer." Tumor Biology 35, no. 8 (2014): 7285–86. http://dx.doi.org/10.1007/s13277-014-2244-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Khatri, Rina G., Kapila Navaratne, and Robert J. Weil. "The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme." Journal of Neurosurgery 109, no. 5 (2008): 842–48. http://dx.doi.org/10.3171/jns/2008/109/11/0842.

Full text

Abstract:

Object Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults, with a 5-year survival rate of < 5%. Aberrant function of TP53 is common in GBM. Although mutational inactivation of p53 is found in many cases, there remain tumors in which genetic alterations of p53 are absent. Negative regulators of the TP53 pathway such as MDM2, which directly inhibits TP53 expression and activity, may influence the pathogenesis of GBM. To understand its potential function in gliomagenesis, the authors analyzed a novel single nucleotide polymorphism (SNP) in the MDM2 promoter that enh

APA, Harvard, Vancouver, ISO, and other styles

22

Thunell, L. K., C. Bivik, P. Waster, et al. "1154 MDM2 SNP309 Confers Risk of Hereditary Melanoma." European Journal of Cancer 48 (July 2012): S277. http://dx.doi.org/10.1016/s0959-8049(12)71750-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Bond, G. L., C. Menin, R. Bertorelle, P. Alhopuro, L. A. Aaltonen, and A. J. Levine. "MDM2 SNP309 accelerates colorectal tumour formation in women." Journal of Medical Genetics 43, no. 12 (2006): 950–52. http://dx.doi.org/10.1136/jmg.2006.043539.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Zou, Xinwei, Yi Zhang, Lin Zhang, et al. "Association between MDM2 SNP309 and endometrial cancer risk." Medicine 97, no. 49 (2018): e13273. http://dx.doi.org/10.1097/md.0000000000013273.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Grochola, Lukasz F., Thomas H. Müller, Gareth L. Bond, Helge Taubert, Andrej Udelnow, and Peter Würl. "MDM2 SNP309 Associates With Accelerated Pancreatic Adenocarcinoma Formation." Pancreas 39, no. 1 (2010): 76–80. http://dx.doi.org/10.1097/mpa.0b013e3181b9f105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Wilkening, Stefan, Justo Lorenzo Bermejo, and Kari Hemminki. "MDM2 SNP309 and cancer risk: a combined analysis." Carcinogenesis 28, no. 11 (2007): 2262–67. http://dx.doi.org/10.1093/carcin/bgm191.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Neto, João Agostinho Machado, Fabiola Traina, Paula Melo Campos, et al. "MDM2 SNP309 and TP53 SNPArg72Pro Polymorphisms in Myelodysplastic Syndrome." Blood 114, no. 22 (2009): 1745. http://dx.doi.org/10.1182/blood.v114.22.1745.1745.

Full text

Abstract:

Abstract Abstract 1745 Poster Board I-771 Introduction Myelodysplastic syndrome (MDS) encompasses a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, refractory cytopenia and a tendency to progress towards acute myeloid leukemia (AML). The progression of the disease may be associated with genetic or epigenetic alterations and a possible change in protein function. MDM2/P53 pathway plays an important role in the control of apoptotic and proliferation mechanisms. Single nucleotide polymorphisms (SNPs) were identified in the TP53 and MDM2

APA, Harvard, Vancouver, ISO, and other styles

28

Leu, Jyh-Der, I.-Feng Lin, Ying-Fang Sun, Su-Mei Chen, Chih-Chao Liu, and Yi-Jang Lee. "Association between MDM2-SNP309 and hepatocellularcarcinoma in Taiwanese population." World Journal of Gastroenterology 15, no. 44 (2009): 5592. http://dx.doi.org/10.3748/wjg.15.5592.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Thunell, Lena K., Cecilia Bivik, Petra Wäster, et al. "MDM2 SNP309 promoter polymorphism confers risk for hereditary melanoma." Melanoma Research 24, no. 3 (2014): 190–97. http://dx.doi.org/10.1097/cmr.0000000000000063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Zhuo, Xianlu, Jie Ren, Dairong Li, Yongzhong Wu, and Qi Zhou. "MDM2 SNP309 variation increases cervical cancer risk among Asians." Tumor Biology 35, no. 6 (2014): 5331–37. http://dx.doi.org/10.1007/s13277-014-1695-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Zenz, Thorsten, Sonja Häbe, Andreas Bühler, et al. "Influence of MDM2 Single Nucleotide Polymorphism SNP309 on Disease Onset and Course in CLL." Blood 108, no. 11 (2006): 4938. http://dx.doi.org/10.1182/blood.v108.11.4938.4938.

Full text

Abstract:

Abstract Background: A SNP in the MDM2 promotor region (SNP309) has been shown to directly influence MDM2 transcript and protein levels with the subsequent attenuation of the p53 pathway. In addition, the GG and GT genotype have been linked to earlier age of onset in patients with different cancers. Because of the well documented prognostic role of p53 in patients with CLL and the potential involvement of MDM2 particularly in patients with trisomy 12, we studied the MDM2 SNP309 in patients with CLL. Methods: We developed a Denaturing High-Performance Liquid Chromatography (DHPLC) assay as a hi

APA, Harvard, Vancouver, ISO, and other styles

32

Asslaber, Daniela, Josefina D. Piñón, Irina Seyfried, et al. "microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia." Blood 115, no. 21 (2010): 4191–97. http://dx.doi.org/10.1182/blood-2009-07-234823.

Full text

Abstract:

In chronic lymphocytic leukemia (B-CLL), aberrations along the p53 axis lead to decreased overall survival and therapy resistance. Recent studies identified microRNA-34a (miR-34a) as a major downstream target of p53. We monitored the expression of miR-34a during disease development in a murine B-CLL model. miR-34a was up-regulated more than 20-fold during the leukemic but not during the preleukemic phase. In the human system, B-CLL cells also had 4.6-fold higher miR-34a expression compared with B cells of healthy controls. In B-CLL cells of patients with p53 aberrations, miR-34a expression was

APA, Harvard, Vancouver, ISO, and other styles

33

Knappskog, Stian, and Per E. Lønning. "MDM2promoter SNP285 and SNP309; phylogeny and impact on cancer risk." Oncotarget 2, no. 3 (2011): 251–58. http://dx.doi.org/10.18632/oncotarget.243.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Cao, Xiangming, Tingrong Zhang, Zhen Zhao, and Tao Zhao. "MDM2 SNP309 Polymorphism and Colorectal Cancer Risk: A Meta-analysis." DNA and Cell Biology 31, no. 3 (2012): 355–59. http://dx.doi.org/10.1089/dna.2011.1338.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Ou, Wen-Bin. "Correlations between MDM2 gene SNP309 Polymorphism and Susceptibility to Leukemia." Medical Science Monitor 21 (2015): 213–18. http://dx.doi.org/10.12659/msm.892919.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Zhang, J. N., S. H. Yi, X. H. Zhang, et al. "Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma." Genetics and Molecular Research 11, no. 4 (2012): 3618–28. http://dx.doi.org/10.4238/2012.october.4.9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Terry, Kathryn, Monica McGrath, I.-Min Lee, Julie Buring, and Immaculata De Vivo. "MDM2 SNP309 Is Associated with Endometrial Cancer Risk: Table 1." Cancer Epidemiology Biomarkers & Prevention 17, no. 4 (2008): 983–86. http://dx.doi.org/10.1158/1055-9965.epi-07-2872.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Duan, Xiaohua, and Jingquan Li. "Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk." Medicine 96, no. 36 (2017): e7856. http://dx.doi.org/10.1097/md.0000000000007856.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Zhao, Erjiang, Dan Cui, Ling Yuan, and Weiquan Lu. "MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis." Molecular Biology Reports 39, no. 4 (2011): 3471–77. http://dx.doi.org/10.1007/s11033-011-1119-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Wasielewski, Marijke, Jord H. A. Nagel, Cecile Brekelmans, et al. "MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling." Breast Cancer Research and Treatment 104, no. 2 (2006): 153–57. http://dx.doi.org/10.1007/s10549-006-9407-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Ezzikouri, Sayeh, Abdellah Essaid El Feydi, Rajae Afifi, et al. "Impact of TP53 Codon 72 and MDM2 Promoter 309 Allelic Dosage in a Moroccan Population with Hepatocellular Carcinoma." International Journal of Biological Markers 26, no. 4 (2011): 229–33. http://dx.doi.org/10.5301/jbm.2011.8881.

Full text

Abstract:

Single-nucleotide polymorphisms (SNPs) in codon 72 of the TP53 gene (rs1042522) and in the promoter region of the MDM2 gene (SNP309; rs2279744) have been shown to play a role in the predisposition to many cancers. However, these findings were inconsistent in other tumor types, and ethnicity is suspected to be a critical factor influencing the effects of these SNPs on the cancer risk. The aim of the present study was to investigate whether these functional SNPs were associated with an enhanced risk of liver tumorigenesis in Moroccan patients. We have genotyped both polymorphisms in 96 patients

APA, Harvard, Vancouver, ISO, and other styles

42

Knappskog, Stian, and Per Eystein Lønning. "Letter to the editor MDM2 SNP309 and risk of endometrial cancer." Polish Journal of Pathology 1 (2013): 69. http://dx.doi.org/10.5114/pjp.2013.34607.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

El Hallani, Soufiane, Yannick Marie, Ahmed Idbaih, et al. "No association of MDM2 SNP309 with risk of glioblastoma and prognosis." Journal of Neuro-Oncology 85, no. 3 (2007): 241–44. http://dx.doi.org/10.1007/s11060-007-9416-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Ma, Yong, Jianmin Bian, and Hongyong Cao. "MDM2 SNP309 rs2279744 Polymorphism and Gastric Cancer Risk: A Meta-Analysis." PLoS ONE 8, no. 2 (2013): e56918. http://dx.doi.org/10.1371/journal.pone.0056918.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Li, Yan, Hongjin Zhao, Li Sun, Linjuan Huang, Qifeng Yang, and Beihua Kong. "MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis." Human Cell 24, no. 2 (2011): 57–64. http://dx.doi.org/10.1007/s13577-011-0013-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Akbarova, Yagut, Munis Dundar, Hilal Akalin, et al. "Analysing the role of MDM2 SNP309 in patients with glioblastoma multiforme." Current Opinion in Biotechnology 24 (July 2013): S98. http://dx.doi.org/10.1016/j.copbio.2013.05.295.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Zając, Agnieszka, Grzegorz Stachowiak, Tomasz Pertyński, Hanna Romanowicz, Jacek Wilczyński, and Beata Smolarz. "Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women." Polish Journal of Pathology 4 (2012): 278–83. http://dx.doi.org/10.5114/pjp.2012.32776.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Nunobiki, Osamu, Hirohide Sawada, and Masatsugu Ueda. "MDM2 SNP309 (rs2279744) and p53 Codon Arg72Pro (rs1042522) SNP in Cervical Carcinogenesis." Advances in Bioscience and Biotechnology 05, no. 07 (2014): 617–22. http://dx.doi.org/10.4236/abb.2014.57072.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

CHEN, WEIFENG, QIANLAN WU, and HONGBO REN. "Meta-analysis of associations between MDM2 SNP309 polymorphism and gastric cancer risk." Biomedical Reports 2, no. 1 (2013): 105–11. http://dx.doi.org/10.3892/br.2013.181.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Boersma, Brenda J., Tiffany M. Howe, Julie E. Goodman, et al. "Association of Breast Cancer Outcome With Status of p53 and MDM2 SNP309." JNCI: Journal of the National Cancer Institute 98, no. 13 (2006): 911–19. http://dx.doi.org/10.1093/jnci/djj245.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!